Pharmacovigilance KPIs: How They Can Assist You

Sep 8, 2020 | Acorn Regulatory News, Pharmacovigilance

How important are pharmacovigilance KPIs in the effective management of a PV system?  We look at the issue and look at how to generate an effective evaluation of your pharmacovigilance system.  This article is an update to an article first written in 2017.

We consider issues such as the criteria that you should be using to determine your KPI’s and we look at the different types of indicators that you need to be aware of.

What Are PV KPI’s?

Pharmacovigilance key performance indicators (PV KPI’s) are a set of quantifiable measures that a company uses to gauge its performance over time. These quantifiable measures can be used to indicate how well a pharmacovigilance system is performing and whether the system is continually improving.

The demands on a PV system vary depending on the number of products concerned, the nature of the products and the life cycle, and regulatory demands placed on the products.

Module I of the GVP Guidance (I.B.12.)– Pharmacovigilance systems and their quality systems require the “Monitoring of the performance and effectiveness of the pharmacovigilance system and its quality system”.

Guidance on compliance monitoring for each pharmacovigilance process is provided in each Module of GVP as appropriate, however, measuring compliance with requirements is not the only way to measure the performance of a PV System.

Too many MAH’s limit the reporting of KPIs to the system’s compliance with reporting timelines (e.g. expedited reporting of ICSRs, PSUR submissions and PRAC Variations).

Generate An Effective Evaluation of Your PV System

In order to generate an effective evaluation of the PV system that will be of value, the following criteria should be considered:

  • Assessments/evaluations should be timely – accounting for the time required for the implementation of e.g. a new procedure/intervention/RMP/Variation
  • Evaluation should address all (relevant) aspects of the PV system
  • The evaluation strategy should include outcomes that can be realistically measured and will not generate inaccurate or misleading data.

Key Performance Indicators

Structural Indicators measure systems and physical infrastructures. These indicators provide an assessment of current PV documentation and resource compliance with regulatory PV expectations and requirements e.g. Existence of Company PV SOPs that reflect current practice, current GVP requirements, and as documented in the PSMF Process Indicators measure how the system works. These provide insight into what extent the PV System is being implemented as planned e.g. SOP/SDEA/PSMF compliance.

Implementation metrics are identified in advance and tracked over time as this helps to support and correct implementation where necessary e.g. by re-training, updating SDEAs, reviewing procedures e.g. Existence of an audited system for coordination and collation of pharmacovigilance data from all sources in the country ( e.g., literature, MAH’s, EMA, CA’s, medical enquiries, complaints).

Outcome Indicators measure the final product of the inputs made into PV activities. These provide an overall measure of the level of risk control (patient safety) that has been achieved with the PV system in place. Examples of these indicators would be; a number of audit findings, a number of PRAC requests for safety updates to patient information, and percentage compliance with safety data reporting timelines.

Key performance indicators should be re-evaluated to assess their relevance as indicators, and targets can be re-set when deemed appropriate.  As a consequence of the monitoring of the PV System performance, corrective and preventive measures can be implemented where deemed necessary, resulting in continuous improvements to the PV System.

Our expert team provides pharmacovigilance support to companies around the world.  If you would like to talk to us about how we might be able to support your company in its PV activities then call us today on 00353 52 61 76 706 or complete your details below and we will get back to you.

Read More

  More Blog Posts

PV Audit Strategy and Risk Assessment

PV Audit Strategy and Risk Assessment

From our experience, companies are falling short of their pharmacovigilance obligations with regards to strategic, tactical and operational level PV audit planning. This can lead to areas of non-compliance, risks to patient safety and inspection findings. Outlined...

read more
BioPharmaChem Impact 24 Conference

BioPharmaChem Impact 24 Conference

We were delighted to attend the 1st ever BioPharmaChem Impact 24 Conference which took place yesterday May 23rd in the beautiful surroundings of Fota Island Resort, Cork.

read more


Subscribe to Our Newsletter

Sign up for our newsletter today and stay informed on the latest regulatory updates and industry insights.